news
Anti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
List view / Grid view
hepatocellular carcinoma (HCC)
news
Treating HCC with genetically modified NK-cell therapy
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
news
Assessing the risk of HCC with machine learning
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
article
Transomics’ impact on a promising liver cancer therapeutic
Using its AI-driven platform, Pepper Bio discovered a promising therapeutic for liver cancer. In this Q&A session with Jon Hu, CEO and co-founder of Pepper Bio, we dive into how the identification of two inhibitors led to a $135M in-licensing deal.
news
Insights into the toxicological effects of nanoparticles
Researchers have developed a system that enabled quantitative assessment of cytotoxicity of SiNPs in human hepatoma cells.
news
Identification of an immune biomarker for liver cancer
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
news
Gene therapy reduces hepatocellular carcinoma in mice
Increasing microRNA-22 overexpression in a gene therapy approach treated HCC in mice, offering promise for its prevention and treatment.
news
Potential new targets for chronic liver disease
Fatty liver disease treatments may become more effective after identification and greater understanding of more drug targets.
news
Protein inhibitor could be new treatment for liver cancer
US scientists have found strong evidence for testing VCU-manufactured drugs in liver cancer.
article
Making cell culture models more physiologically relevant
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
article
Why invest in creating a modifiable drug framework?
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.